Evidence map›Paper›PMID 33088844›Full record

ArticleJournal of health economics and outcomes research2020

Estimating the Burden of Illness Related to Genital Warts in Russia: A Cross-Sectional Study.

Vera N Prilepskaya, Mikhail Gomberg, Smita Kothari, Karen Yee, Amit Kulkarni, Suzanne M Garland, Anna R Giuliano

Open access · goldAbstract read
In one paragraph

Article in Journal of health economics and outcomes research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Vera N PrilepskayaMinistry of Healthcare of the Russian Federation, Research Center for Obstetrics, Gynecology, and Perinatology, Moscow, Russia.
Mikhail GombergMoscow Scientific and Practical Center for Dermatovenerology and Cosmetology, Moscow, Russia.
Smita KothariMerck & Co. Inc., Kenilworth, NJ, USA.
Karen YeeCubist Pharmaceuticals, Lexington, MA, USA.
Amit KulkarniMerck & Co. Inc., Kenilworth, NJ, USA.
Suzanne M GarlandThe Royal Women's Hospital, Murdoch Childrens Research Institute, Department of Obstetrics and Gynecology, University of Melbourne, Parkville, Victoria, Australia.
Anna R GiulianoCenter for Infection Research in Cancer (CIRC) at Moffitt Cancer Center, Tampa, FL, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USCubist Pharmaceuticals (United States) · USMoffitt Cancer Center · USMurdoch Children's Research Institute · AUNational Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov of the Ministry of Healthcare of the Russian Federation · RUState Research Center for Dermatovenereology and Cosmetology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman papillomavirus (HPV) infections are the etiologic agents of genital warts (GW). HPV is one of the most frequent sexually transmitted viral infections, and nearly 65% of individuals with partners who have GW also develop GW. In Russia, as in many other countries, overall GW prevalence data are scarce. Given the lack of Russian data, our study estimated GW prevalence in physician practices and GW-related health care resource use in Russia among male and female patients aged 18-60 years.

methodsRussian physicians recorded daily patient logs for a two-week period and conducted a 30-minute survey to estimate GW prevalence and related resource use between January and June 2012. Age, gender, and GW diagnosis status was recorded. Prevalence was obtained for each physician and calculated into a single estimate across all physician types. Overall prevalence estimate and 95% confidence interval were weighted by the estimated number of physicians in each specialty and the proportion of total patients visiting each specialist type. Health care resource use was reported and compared among different physician specialties.

resultsThe overall GW prevalence estimate was 9162 cases per 100 000 for male and female patients aged 18-60 years, with 9917 for obstetrician/gynecologists (OB/GYN), 8298 for urologists (URO), and 7833 for dermatologists (DERM). For males, GW prevalence was 8769 cases per 100 000, with the highest prevalence in the 30-34 age group. In females, GW prevalence was 9304 cases per 100 000, with the highest prevalence in the 18-24 age group. Among overall existing GW cases, 63.1% were recurrent and 34.2% were resistant. For all patients in our study, GW prevalence was higher in females. Male patients had the highest prevalence for those aged 30-34 years, and female patients for those aged 18-24 years. These results are consistent with data reported in other countries. Study limitations include estimates and results representative of the urban population of Russia. Despite its limitations, this study provides a GW prevalence estimate in Russia not previously available.

conclusionsGW is a significant public health concern in Russia, and the GW prevalence was higher in female patients compared to male patients.

Indexed as

CondylomaDisease PreventionHuman Papillomavirus (HPV)Infectious DiseasesVaccine

Identifiers

PMID33088844
PMCPMC7549541
OpenAlexW3091832295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.